Home › Encyclopedia › Gonadorelin: Uses, Evidence, and Clinical Data
Approved

Gonadorelin: Uses, Evidence, and Clinical Data

Molecular formulaC55H75N17O13
Molecular weight1182.3 g/mol
Registered trials1335
PubChem CID638793

Anyone researching gonadorelin usually wants to know what it actually is and how extensively it has been studied. This overview summarizes what is publicly documented about the compound's identity and trial activity.

Key takeaways

  • Gonadorelin is a synthetic peptide with the molecular formula C55H75N17O13.
  • It has a molecular weight of approximately 1,182.3 g/mol.
  • More than 1,300 registered clinical trials reference gonadorelin or related compounds.
  • Sample trial data includes completed Phase 2 studies in endometriosis and prostate cancer research.

What gonadorelin is

Gonadorelin is a synthetic decapeptide identified in chemical databases under PubChem CID 638793. Its structure places it among peptide hormone analogs studied in reproductive and endocrine research contexts.

What the evidence shows

Public trial registries list 1,335 registered studies referencing gonadorelin or closely related compounds. Among the sampled trials, a Phase 2 study evaluating TAK-385 for endometriosis reached completed status. Another Phase 2 trial examining tecemotide (L-BLP25) in prostate cancer also completed. A separate study on superovulation stimulation protocols using human chorionic gonadotropin is currently enrolling by invitation, reflecting ongoing interest in related reproductive endocrinology research.

FAQ

What is gonadorelin?
Gonadorelin is a synthetic decapeptide with the molecular formula C55H75N17O13 and a molecular weight of about 1,182.3 g/mol. It is cataloged in chemical databases under PubChem CID 638793.
How many clinical trials have studied gonadorelin?
Public registries list 1,335 registered clinical trials referencing gonadorelin or closely related compounds. These span a range of study phases and statuses, including completed and enrolling trials.
Has gonadorelin been studied for endometriosis?
A Phase 2 trial evaluating TAK-385 for endometriosis treatment has reached completed status. This is one example from the broader set of registered studies involving related compounds.
Is there research linking gonadorelin to prostate cancer studies?
Yes, a completed Phase 2 trial examined tecemotide (L-BLP25) in the context of prostate cancer. This reflects the broader research interest in hormone-related pathways relevant to gonadorelin research.
Are there ongoing studies related to gonadorelin?
Yes, at least one trial involving superovulation stimulation protocols is currently enrolling by invitation. This indicates continued research activity in related reproductive endocrinology areas.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem ClinicalTrials.gov

Updated 2026-09-19